Floatz logo

Osimertinib

Non-Small Cell Lung Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Small moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
65/ 100

Competitive context

1127 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Osimertinib is also rated in:

lung adenocarcinomaDormant
BB
Indicative · Phase 2
69 / 100
View asset →
hepatocellular carcinomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
adenocarcinomaActive
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →